Uninephrectomy reduces 11β-hydroxysteroid dehydrogenase type 1 and type 2 concomitantly with an increase in blood pressure in rats

Journal of Endocrinology

Volumn 214, Issue 3, 2012, Pages 373-380

  Lauterburg, M ^a   Escher, G ^a   Dick, B ^a   Ackermann, D ^a   Frey, F J ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; CORTICOSTERONE; CREATININE; DEHYDROCORTICOSTERONE; GLUCOCORTICOID; MESSENGER RNA;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CREATININE CLEARANCE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART RATE; HYPERTENSION; KIDNEY ALLOGRAFT; MALE; MASS FRAGMENTOGRAPHY; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHAM PROCEDURE; TELEMETRY; UNINEPHRECTOMY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ALDOSTERONE; ANIMALS; BLOOD PRESSURE; CORTICOSTERONE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYPERTENSION, RENAL; KIDNEY; MALE; NEPHRECTOMY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84866274753     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0200     Document Type: Article

References (45)

1. Albiston AL, Obeyesekere VR, Smith RE & Krozowski ZS 1994 Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Molecular and Cellular Endocrinology 105 R11-R17.
2. Alikhani-Koopaei R, Fouladkou F, Frey FJ & Frey BM. 2004 Epigenetic regulation of 11β-hydroxysteroid dehydrogenase type 2 expression. Journal of Clinical Investigation 114 1146-1157.
3. Alikhani-Koupaei R, Fouladkou F, Fustier P, Cenni B, Sharma AM, Deter HC, Frey BM & Frey FJ. 2007 Identification of polymorphisms in the human 11β-hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity. FASEB Journal 21 3618-3628.
4. Anderson S, Meyer TW, Rennke HG & Brenner BM. 1985 Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. Journal of Clinical Investigation 76 612-619.
5. Atanasov AG, Ignatova ID, Nashev LG, Dick B, Ferrari P, Frey FJ & Odermatt A. 2007 Impaired protein stability of 11β-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. Journal of the American Society of Nephrology 18 1262-1270.
6. Bailey MA, Paterson JM, Hadoke PW, Wrobel N, Bellamy CO, Brownstein DG, Seckl JR & Mullins JJ. 2008 A switch in the mechanism of hypertension in the syndrome of apparent mineralocorticoid excess. Journal of the American Society of Nephrology 19 47-58.
7. Best R & Walker BR. 1997 Additional value of measurement of urinary cortisone and unconjugated cortisol metabolites in assessing the activity of 11β-hydroxysteroid dehydrogenase in vivo. Clinical Endocrinology 47 231-236.
8. Boudville N, Prasad GV, Knoll G, Muirhead N, Thiessen-Philbrook H, Yang RC, Rosas-Arellano MP, Housawi A & Garg AX. 2006 Metaanalysis: risk for hypertension in living kidney donors. Annals of Internal Medicine 145 185-196.
9. Carlstrom M, Sallstrom J, Skott O, Larsson E & Persson AE. 2007 Uninephrectomy in young age or chronic salt loading causes salt-sensitive hypertension in adult rats. Hypertension 49 1342-1350.
10. Davis CL. 2009 Living kidney donors: current state of affairs. Advances in Chronic Kidney Disease 16 242-249.
11. Deen WM, Maddox DA, Robertson CR & Brenner BM. 1974 Dynamics of glomerular ultrafiltration in the rat. VII. Response to reduced renal mass. American Journal of Physiology 227 556-562.
12. Draper N & Stewart PM. 2005 11β-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. Journal of Endocrinology 186 251-271.
13. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER & Monder C. 1988 Localisation of 11β-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet 2 986-989.
14. Escher G, Nawrocki A, Staub T, Vishwanath BS, Frey BM, Reichen J & Frey FJ. 1998a Down-regulation of hepatic and renal 11β-hydroxysteroid dehydrogenase in rats with liver cirrhosis. Gastroenterology 114 175-184.
15. Escher G, Vogt B, Beck T, Guntern D, Frey BM & Frey FJ. 1998b Reduced 11β-hydroxysteroid dehydrogenase activity in the remaining kidney following nephrectomy. Endocrinology 139 1533-1539.
16. Ferrari P. 2010 The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension. Biochimica et Biophysica Acta 1802 1178-1187.
17. Ferreira-Filho SR, da Silva Passos L & Ribeiro MB. 2007 Corporeal weight gain and metabolic syndrome in living kidney donors after nephrectomy. Transplantation Proceedings 39 403-406.
18. Funder JW, Pearce PT, Smith R & Smith AI. 1988 Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242 583-585.
19. Ge R, Huang Y, Liang G & Li X. 2010 11β-Hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development. Current Medicinal Chemistry 17 412-422.
20. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA & Brenner BM. 1981 Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. American Journal of Physiology 241 F85-F93.
21. Ibrahim HN, Foley R, Tan L, Rogers T, Bailey RF, Guo H, Gross CR & Matas AJ. 2009 Long-term consequences of kidney donation. New England Journal of Medicine 360 459-469.
22. Ignatova ID, Kostadinova RM, Goldring CE, Nawrocki AR, Frey FJ & Frey BM. 2009 Tumor necrosis factor a upregulates 11β-hydroxysteroid dehydrogenase type 1 expression by CCAAT/enhancer binding protein-β in HepG2 cells. American Journal of Physiology. Endocrinology and Metabolism 296 E367-E377.
23. Jamieson PM, Chapman KE, Edwards CR & Seckl JR. 1995 11β-Hydroxysteroid dehydrogenase is an exclusive 11β-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 136 4754-4761.
24. Kostadinova RM, Nawrocki AR, Frey FJ & Frey BM. 2005 Tumor necrosis factor α and phorbol 12-myristate-13-acetate down-regulate human 11β-hydroxysteroid dehydrogenase type 2 through p50/p50 NF-kappaB homodimers and Egr-1. FASEB Journal. 19 650-652.
25. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR et al. 1997 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoidinducible responses and resist hyperglycemia on obesity or stress. PNAS 94 14924-14929.
26. Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CR, Seckl JR & Mullins JJ. 1999 Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2. Journal of Clinical Investigation 103 683-689.
27. Kujubu DA, Norman JT, Herschman HR & Fine LG. 1991 Primary response gene expression in renal hypertrophy and hyperplasia: evidence for different growth initiation processes. American Journal of Physiology 260 F823-F827.
28. Lakshmi V & Monder C. 1988 Purification and characterization of the corticosteroid 11β-dehydrogenase component of the rat liver 11β-hydroxysteroid dehydrogenase complex. Endocrinology 123 2390-2398.
29. Latif SA, Pardo HA, Hardy MP & Morris DJ. 2005 Endogenous selective inhibitors of 11β-hydroxysteroid dehydrogenase isoforms 1 and 2 of adrenal origin. Molecular and Cellular Endocrinology 243 43-50.
30. Low SC, Chapman KE, Edwards CR & Seckl JR. 1994 'Liver-type' 11β-hydroxysteroid dehydrogenase cDNA encodes reductase but not dehydrogenase activity in intact mammalian COS-7 cells. Journal of Molecular Endocrinology 13 167-174.
31. Mimran A, Mourad G & Ribstein J. 1993 Early systemic and renal responses to nephrectomy in normotensive kidney donors. Nephrology, Dialysis, Transplantation 8 448-453.
32. Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ & Seckl JR. 2001 Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. Journal of Biological Chemistry 276 41293-41300.
33. Palermo M, Shackleton CH, Mantero F & Stewart PM. 1996 Urinary free cortisone and the assessment of 11β-hydroxysteroid dehydrogenase activity in man. Clinical Endocrinology 45 605-611.
34. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR & Mullins JJ. 2004 Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. PNAS 101 7088-7093.
35. Paterson JM, Seckl JR & Mullins JJ. 2005 Genetic manipulation of 11β-hydroxysteroid dehydrogenases in mice. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 289 R642-R652.
36. Pupilli C, Chevalier RL, Carey RM & Gomez RA. 1992 Distribution and content of renin and renin mRNA in remnant kidney of adult rat. American Journal of Physiology 263 F731-F738.
37. Recordati G, Zorzoli F & Zanchetti A. 2000 Effects of a reversible 'nephrectomy' on renal sympathetic activity and blood pressure in the rat: evidence for an acute angiotensin-mediated hypertension. Journal of Hypertension 18 1277-1287.
38. Schumacher M, Frey FJ, Montani JP, Dick B, Frey BM & Ferrari P. 2002 Salt-sensitivity of blood pressure and decreased 11β-hydroxysteroid dehydrogenase type 2 activity after renal transplantation. Transplantation 74 66-72.
39. Shackleton CH. 1993 Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research. Journal of Steroid Biochemistry and Molecular Biology 45 127-140.
40. Talseth T, Fauchald P, Skrede S, Djoseland O, Berg KJ, Stenstrom J, Heilo A, Brodwall EK & Flatmark A. 1986 Long-term blood pressure and renal function in kidney donors. Kidney International 29 1072-1076.
41. Tang JI, Kenyon CJ, Seckl JR & Nyirenda MJ. 2011 Prenatal overexposure to glucocorticoids programs renal 11β-hydroxysteroid dehydrogenase type 2 expression and salt-sensitive hypertension in the rat. Journal of Hypertension 29 282-289.
42. Tomlinson DC, Grindley JC & Thomson AA. 2004 Regulation of Fgf10 gene expression in the prostate: identification of transforming growth factor-β1 and promoter elements. Endocrinology 145. 1988-1995.
43. Wake DJ, Stimson RH, Tan GD, Homer NZ, Andrew R, Karpe F & Walker BR. 2007 Effects of peroxisome proliferator-activated receptor-α and -γ agonists on 11β-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men. Journal of Clinical Endocrinology and Metabolism 92 1848-1856.
44. Woods LL. 1999 Neonatal uninephrectomy causes hypertension in adult rats. American Journal of Physiology 276 R974-R978.
45. Zhang ZH, Kang YM, Yu Y, Wei SG, Schmidt TJ, Johnson AK & Felder RB. 2006 11β-Hydroxysteroid dehydrogenase type 2 activity in hypothalamic paraventricular nucleus modulates sympathetic excitation. Hypertension 48 127-133.